Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

Lund University researcher discovers new sepsis biomarker in blood

Sepsis is the name of an infection that causes a series of reactions in the body, which in the worst case can prove fatal. The problem for both patients and doctors is that the early symptoms are difficult to distinguish from less dangerous infections such as a severe flu or winter vomiting disease.

23 May 2011

FDA approves SUTENT for treatment of pancreatic NET

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.

21 May 2011

Feeding SimplyThick to premature infants may cause NEC, warns FDA

FDA is warning parents, caregivers and health care providers not to feed SimplyThick, a thickening agent for management of swallowing disorders, to infants born before 37 weeks.

21 May 2011

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

The U.S. Food and Drug Administration today approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

21 May 2011

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

20 May 2011

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

The U.S. Food and Drug Administration today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of the ACCORD Lipid study as they relate to the use of fenofibric acid (sold as Trilipix in the United States) in combination with a statin in patients with mixed dyslipidemia and at high risk of heart disease.

20 May 2011

Caring Online offers comprehensive and informative website on adult eating disorders

Are you aware that eating disorders affect more than 10 million people in this country, and that bulimia, anorexia, binge eating and other destructive food behaviors are not exclusive to the youth? These serious and often deadly afflictions have become a growing problem with midlife adults and older, often more difficult to detect as adults are expected to have it "all together."

19 May 2011

AstraZeneca announces encouraging results from olaparib phase II study in serous ovarian cancer

AstraZeneca announced today encouraging results from a phase II study in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) who had received maintenance treatment with the investigational drug olaparib, after the completion of chemotherapy.

19 May 2011

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma, axitinib significantly extended progression-free survival at the 47th Annual American Society of Clinical Oncology meeting in Chicago from June 3-7, 2011.

19 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

Decision on destroying last of the stored small pox virus samples

Health experts from all over the world are to decide this week whether to hold on to the last remaining stockpiles of smallpox, one of the deadliest diseases in history – or to proceed with their destruction.

17 May 2011

Eli Lilly responds to Amylin's exenatide lawsuit

Eli Lilly and Company has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s lawsuit filed in the United States District Court for the Southern District of California.

17 May 2011

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

AstraZeneca today announced results from a long-term study comparing SYMBICORT Inhalation Aerosol 160/4.5 mcg with budesonide pressurized metered-dose inhaler 160 mcg in self-reported African American patients with moderate to severe persistent asthma.

17 May 2011

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin Pharmaceuticals, Inc. today announced that it has filed a lawsuit against Eli Lilly and Company in the United States District Court for the Southern District of California, alleging that Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide.

16 May 2011

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that positive results from its Phase 3 study evaluating EXPAREL in patients following hemorrhoidectomy will be presented at the 2011 American Society of Colon and Rectal Surgeons Annual Scientific Meeting in Vancouver, British Columbia.

16 May 2011

Health Canada approves EMEND IV formulation to prevent chemotherapy-induced nausea, vomiting

Today Merck announced that Health Canada has approved the new intravenous formulation of EMEND IV. Used in combination with a 5-HT3 antagonist class of antiemetics and dexamethasone, fosaprepitant dimeglumine is indicated for the prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy.

12 May 2011

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL, and reiterated 2011 financial guidance.

11 May 2011

Study finds strong link between live birth rates and number of eggs retrieved in one IVF cycle

An analysis of over 400,000 IVF cycles in the UK has shown that doctors should aim to retrieve around 15 eggs from a woman's ovaries in a single cycle in order to have the best chance of achieving a live birth after assisted reproduction technology.

11 May 2011

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

BioAlliance Pharma, a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. for commercialization rights in Japan for Loramyc muco-adhesive buccal tablet.

11 May 2011

Vomiting News and Research

Further Reading

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Lund University researcher discovers new sepsis biomarker in blood

FDA approves SUTENT for treatment of pancreatic NET

Feeding SimplyThick to premature infants may cause NEC, warns FDA

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

Caring Online offers comprehensive and informative website on adult eating disorders

AstraZeneca announces encouraging results from olaparib phase II study in serous ovarian cancer

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Decision on destroying last of the stored small pox virus samples

Eli Lilly responds to Amylin's exenatide lawsuit

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Health Canada approves EMEND IV formulation to prevent chemotherapy-induced nausea, vomiting

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

Study finds strong link between live birth rates and number of eggs retrieved in one IVF cycle

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News